Do analysts prefer VBIO or VTGN?

VistaGen Therapeutics has a consensus price target of $0.95, suggesting a potential upside of 285.87%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe VistaGen Therapeutics is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VistaGen Therapeutics 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Does the media prefer VBIO or VTGN?

In the previous week, Valion Bio, Inc. Common Stock had 2 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 1 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.00 beat Valion Bio, Inc. Common Stock's score of -0.40 indicating that VistaGen Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valion Bio, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral VistaGen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate GDTC or VBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, GDTC or VBIO?

CytoMed Therapeutics has higher earnings, but lower revenue than Valion Bio, Inc. Common Stock. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CytoMed Therapeutics $250K 42.26 -$3.10M N/A N/A Valion Bio, Inc. Common Stock $780K 3.19 -$8.88M -$6.37 N/A

Is GDTC or VBIO more profitable?

CytoMed Therapeutics' return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets CytoMed Therapeutics N/A N/A N/A Valion Bio, Inc. Common Stock N/A -193.17% -67.10%

Do analysts prefer VBIO or INAB?

IN8bio has a consensus price target of $4.00, indicating a potential upside of 244.83%. Given IN8bio's stronger consensus rating and higher probable upside, analysts plainly believe IN8bio is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is VBIO or INAB more profitable?

IN8bio's return on equity of -91.18% beat Valion Bio, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Valion Bio, Inc. Common Stock N/A -193.17% -67.10% IN8bio N/A -91.18% -76.93%

Do analysts rate VBIO or SNTI?

Senti Biosciences has a consensus target price of $10.00, indicating a potential upside of 2,831.69%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Senti Biosciences is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Is VBIO or SNTI more profitable?

Valion Bio, Inc. Common Stock's return on equity of -193.17% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Valion Bio, Inc. Common Stock N/A -193.17% -67.10% Senti Biosciences N/A -1,629.80% -119.72%

Do analysts recommend APRE or VBIO?

Aprea Therapeutics presently has a consensus price target of $3.07, suggesting a potential upside of 280.34%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Aprea Therapeutics is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor APRE or VBIO?

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than Aprea Therapeutics. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 2 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.06 beat Valion Bio, Inc. Common Stock's score of -0.40 indicating that Aprea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aprea Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Valion Bio, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Valion Bio, Inc. Common Stock (VBIO) Competitors

$2.80 -0.32 (-10.26%)

As of 09/3/2026 04:00 PM Eastern

Compare

VBIO vs. VTGN, GDTC, INAB, SNTI, and APRE

Should you buy Valion Bio, Inc. Common Stock stock or one of its competitors? Valion Bio, Inc. Common Stock's main competitors and comparable companies include VistaGen Therapeutics (VTGN), CytoMed Therapeutics (GDTC), IN8bio (INAB), Senti Biosciences (SNTI), and Aprea Therapeutics (APRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Valion Bio, Inc. Common Stock compare to VistaGen Therapeutics?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than VistaGen Therapeutics. Valion Bio, Inc. Common Stock is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780K	3.19	-$8.88M	-$6.37	N/A
VistaGen Therapeutics	$1.27M	8.60	-$69.68M	-$1.66	N/A

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -2,702.64%. VistaGen Therapeutics' return on equity of -152.59% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%

4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are held by institutional investors. 2.5% of Valion Bio, Inc. Common Stock shares are held by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valion Bio, Inc. Common Stock has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

In the previous week, Valion Bio, Inc. Common Stock had 2 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 1 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.00 beat Valion Bio, Inc. Common Stock's score of -0.40 indicating that VistaGen Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VistaGen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

VistaGen Therapeutics has a consensus price target of $0.95, suggesting a potential upside of 285.87%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe VistaGen Therapeutics is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

VistaGen Therapeutics beats Valion Bio, Inc. Common Stock on 10 of the 15 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to CytoMed Therapeutics?

CytoMed Therapeutics (NASDAQ:GDTC) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

CytoMed Therapeutics has higher earnings, but lower revenue than Valion Bio, Inc. Common Stock.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytoMed Therapeutics	$250K	42.26	-$3.10M	N/A	N/A
Valion Bio, Inc. Common Stock	$780K	3.19	-$8.88M	-$6.37	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CytoMed Therapeutics' return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytoMed Therapeutics	N/A	N/A	N/A
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%

0.0% of CytoMed Therapeutics shares are owned by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. 2.5% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Valion Bio, Inc. Common Stock had 3 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 0 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 0.00 beat Valion Bio, Inc. Common Stock's score of -0.40 indicating that CytoMed Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
CytoMed Therapeutics	Neutral
Valion Bio, Inc. Common Stock	Neutral

CytoMed Therapeutics has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

Summary

CytoMed Therapeutics and Valion Bio, Inc. Common Stock tied by winning 5 of the 10 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to IN8bio?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and IN8bio (NASDAQ:INAB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

IN8bio's return on equity of -91.18% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%
IN8bio	N/A	-91.18%	-76.93%

In the previous week, Valion Bio, Inc. Common Stock had 3 more articles in the media than IN8bio. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 0 mentions for IN8bio. IN8bio's average media sentiment score of 0.00 beat Valion Bio, Inc. Common Stock's score of -0.40 indicating that IN8bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Valion Bio, Inc. Common Stock	Neutral
IN8bio	Neutral

Valion Bio, Inc. Common Stock has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, IN8bio has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market.

IN8bio has a consensus price target of $4.00, indicating a potential upside of 244.83%. Given IN8bio's stronger consensus rating and higher probable upside, analysts plainly believe IN8bio is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 2.5% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Comparatively, 14.5% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valion Bio, Inc. Common Stock has higher revenue and earnings than IN8bio. IN8bio is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780K	3.19	-$8.88M	-$6.37	N/A
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A

Summary

IN8bio beats Valion Bio, Inc. Common Stock on 8 of the 14 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Senti Biosciences?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and Senti Biosciences (NASDAQ:SNTI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

Valion Bio, Inc. Common Stock's return on equity of -193.17% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%
Senti Biosciences	N/A	-1,629.80%	-119.72%

4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 2.5% of Valion Bio, Inc. Common Stock shares are held by insiders. Comparatively, 3.1% of Senti Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Valion Bio, Inc. Common Stock had 3 more articles in the media than Senti Biosciences. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 0 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 0.00 beat Valion Bio, Inc. Common Stock's score of -0.40 indicating that Senti Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Valion Bio, Inc. Common Stock	Neutral
Senti Biosciences	Neutral

Valion Bio, Inc. Common Stock has higher revenue and earnings than Senti Biosciences. Valion Bio, Inc. Common Stock is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780K	3.19	-$8.88M	-$6.37	N/A
Senti Biosciences	$20K	531.26	-$61.44M	-$1.77	N/A

Senti Biosciences has a consensus target price of $10.00, indicating a potential upside of 2,831.69%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Senti Biosciences is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Valion Bio, Inc. Common Stock has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.12, indicating that its share price is 112% more volatile than the broader market.

Summary

Senti Biosciences beats Valion Bio, Inc. Common Stock on 11 of the 16 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Aprea Therapeutics?

Aprea Therapeutics (NASDAQ:APRE) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Aprea Therapeutics has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

Valion Bio, Inc. Common Stock has higher revenue and earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290K	35.00	-$12.60M	-$1.08	N/A
Valion Bio, Inc. Common Stock	$780K	3.19	-$8.88M	-$6.37	N/A

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -47.60% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than Aprea Therapeutics. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 2 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.06 beat Valion Bio, Inc. Common Stock's score of -0.40 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aprea Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 10.5% of Aprea Therapeutics shares are held by insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aprea Therapeutics presently has a consensus price target of $3.07, suggesting a potential upside of 280.34%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Aprea Therapeutics is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Aprea Therapeutics beats Valion Bio, Inc. Common Stock on 10 of the 16 factors compared between the two stocks.

Get Valion Bio, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VBIO vs. The Competition

Export

Metric	Valion Bio, Inc. Common Stock	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.77M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.44	12.66	273.29	25.38
Price / Sales	3.19	1,309.08	613.45	92.55
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	0.59	16.29	12.89	6.14
Net Income	-$8.88M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-7.36%	0.34%	0.60%	-0.27%
1 Month Performance	-66.30%	8.52%	5.73%	0.68%
1 Year Performance	-96.15%	52.66%	25.35%	14.84%

Valion Bio, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VBIO Valion Bio, Inc. Common Stock	0.2954 of 5 stars	$2.80 -10.3%	N/A	-96.3%	$2.77M	$780K	N/A	10	Gap Down
VTGN VistaGen Therapeutics	1.9259 of 5 stars	$0.25 +1.1%	$0.95 +286.2%	-93.3%	$10.80M	$1.27M	N/A	40	Gap Up
GDTC CytoMed Therapeutics	0.4208 of 5 stars	$0.90 -1.4%	N/A	-54.3%	$10.75M	$250K	N/A	N/A	Gap Down
INAB IN8bio	2.3811 of 5 stars	$1.10 +0.9%	$4.00 +263.6%	-47.5%	$10.75M	N/A	N/A	20
SNTI Senti Biosciences	2.9 of 5 stars	$0.34 +0.6%	$10.00 +2,824.8%	-76.4%	$10.59M	$20K	N/A	4

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VBIO) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Valion Bio, Inc. Common Stock (VBIO) Competitors

VBIO vs. VTGN, GDTC, INAB, SNTI, and APRE

How does Valion Bio, Inc. Common Stock compare to VistaGen Therapeutics?

Summary

How does Valion Bio, Inc. Common Stock compare to CytoMed Therapeutics?

Summary

How does Valion Bio, Inc. Common Stock compare to IN8bio?

Summary

How does Valion Bio, Inc. Common Stock compare to Senti Biosciences?

Summary

How does Valion Bio, Inc. Common Stock compare to Aprea Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO vs. The Competition

Valion Bio, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Valion Bio, Inc. Common Stock (VBIO) Competitors

VBIO vs. VTGN, GDTC, INAB, SNTI, and APRE

How does Valion Bio, Inc. Common Stock compare to VistaGen Therapeutics?

Which has preferable valuation & earnings, VBIO or VTGN?

Is VBIO or VTGN more profitable?

Do insiders & institutionals hold more shares of VBIO or VTGN?

Which has more volatility and risk, VBIO or VTGN?

Does the media prefer VBIO or VTGN?

Do analysts prefer VBIO or VTGN?

Summary

How does Valion Bio, Inc. Common Stock compare to CytoMed Therapeutics?

Which has better earnings & valuation, GDTC or VBIO?

Do analysts rate GDTC or VBIO?

Is GDTC or VBIO more profitable?

Do institutionals and insiders hold more shares of GDTC or VBIO?

Does the media favor GDTC or VBIO?

Which has more risk and volatility, GDTC or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to IN8bio?

Is VBIO or INAB more profitable?

Does the media refer more to VBIO or INAB?

Which has more volatility & risk, VBIO or INAB?

Do analysts prefer VBIO or INAB?

Do institutionals & insiders believe in VBIO or INAB?

Which has preferable earnings & valuation, VBIO or INAB?

Summary

How does Valion Bio, Inc. Common Stock compare to Senti Biosciences?

Is VBIO or SNTI more profitable?

Do insiders & institutionals believe in VBIO or SNTI?

Does the media refer more to VBIO or SNTI?

Which has better valuation and earnings, VBIO or SNTI?

Do analysts rate VBIO or SNTI?

Which has more volatility & risk, VBIO or SNTI?

Summary

How does Valion Bio, Inc. Common Stock compare to Aprea Therapeutics?

Which has more risk and volatility, APRE or VBIO?

Which has stronger valuation & earnings, APRE or VBIO?

Is APRE or VBIO more profitable?

Does the media favor APRE or VBIO?

Do institutionals and insiders have more ownership in APRE or VBIO?

Do analysts recommend APRE or VBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO vs. The Competition

Valion Bio, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools